Monday, July 31, 2017 7:29:06 AM
FDA's Plan to Lower Nicotine in Cigarettes to Non-Addictive Levels Shines Spotlight on 22nd Century Group
22nd Century Group, Inc. (AMEX:XXII)
Today : Monday 31 July 2017
22nd Century is the only company in the world capable of growing tobacco with non-addictive levels of nicotine.
22nd Century Group, Inc. (NYSE American:XXII), a plant biotechnology company that is focused on tobacco harm reduction, stated today that the Company welcomes the announcement by the United States Food and Drug Administration (FDA) that the Agency is exercising its authority under the Family Smoking Prevention and Tobacco Control Act to mandate lower nicotine – at non-addictive levels – in combustible cigarettes sold in the United States.
22nd Century is already capable of achieving the FDA’s ambitious new product standard. As previously reported, 22nd Century is the only company in the world capable of growing tobacco with non-addictive levels of nicotine. The Company’s proprietary Very Low Nicotine tobacco is grown on independently-owned farms in the United States – without any artificial extraction or chemical processes.
22nd Century uses its proprietary and patent-protected Very Low Nicotine tobacco to produce the world’s lowest nicotine tobacco cigarettes. 22nd Century’s Very Low Nicotine cigarettes contain less than 0.6 mg nicotine per cigarette and less than 0.05 mg nicotine yield per cigarette. In each case, this represents a reduction of at least 95% less nicotine relative to “Big Tobacco” cigarette brands, including Marlboro®, Camel®, Newport®, and American Spirit®. 22nd Century’s Very Low Nicotine cigarettes have the taste and sensory characteristics of conventional cigarettes, but contain only trace amounts of nicotine so that smokers’ exposure to nicotine is reduced drastically.
In the FDA announcement on July 28, 2017, FDA Commissioner Scott Gottlieb, M.D., stated that “The overwhelming amount of death and disease attributable to tobacco is caused by addiction to cigarettes – the only legal consumer product that, when used as intended, will kill half of all long-term users. Unless we change course, 5.6 million young people alive today will die prematurely later in life from tobacco use. Envisioning a world where cigarettes would no longer create or sustain addiction, and where adults who still need or want nicotine could get it from alternative and less harmful sources, needs to be the cornerstone of our efforts – and we believe it's vital that we pursue this common ground."
In a June 16, 2010 press release, Dr. David Kessler, the former FDA Commissioner, recommended that “[t]he FDA should quickly move to reduce nicotine levels in cigarettes to non-addictive levels. If we reduce the level of the stimulus, we reduce the craving. It is the ultimate harm reduction strategy.” Shortly thereafter, in a Washington Post newspaper article, Dr. Kessler said that the amount of nicotine in a cigarette should drop from about 10 milligrams to less than 1 milligram. By producing cigarettes that contain less than 0.6 mg of nicotine per cigarette, 22nd Century has already met Dr. Kessler’s standard and has simultaneously demonstrated that the FDA’s targets are both technically achievable and realistic.
In order to provide public health officials, tobacco industry competitors, and the general public with compelling scientific data in support of Very Low Nicotine cigarettes, 22nd Century has partnered with independent researchers and officials from the FDA, the National Institute of Drug Abuse (NIDA), the National Cancer Institute (NCI), and the Centers for Disease Control and Prevention (CDC), to develop SPECTRUM® brand research cigarettes.
22nd Century has already delivered more than 22 million SPECTRUM cigarettes and recently received a new purchase order for 2.4 million additional government research cigarettes. Utilized by dozens of independent scientists and researchers over the past several years, the SPECTRUM product line consists of a series of cigarette styles that vary nicotine yields over a 50-fold range – from very low (97% less nicotine than conventional brands) to relatively high nicotine yields. 22nd Century is the only company in the world capable of producing the Very Low Nicotine SPECTRUM brand styles. Separate from the SPECTRUM research cigarettes program, 22nd Century was also chosen to supply the Company’s proprietary Very Low Nicotine fine cut tobacco to the FDA for additional research.
Agencies of the U.S. federal government have invested more than $100 million on independent clinical research with SPECTRUM cigarettes that supports the conclusion that lowering nicotine levels in combustible tobacco cigarettes would drastically improve public health. Public health policy reform advocates, Drs. Michael Fiore and Timothy Baker wrote in The New England Journal of Medicine: “Reducing the nicotine content of combustible tobacco to levels that will not sustain dependence seems to us to be the most promising regulatory policy option for preventing [at least] 20 million premature deaths.”
Building on the large and growing body of clinical research in support of Very Low Nicotine cigarettes, the World Health Organization (WHO) cited 22nd Century’s proprietary tobacco cigarettes in its recommendation that all WHO-member countries mandate reductions in nicotine in combustible tobacco cigarettes to non-addictive levels.
A landmark clinical study cited by WHO in its recommendation – and likely influential in FDA’s stated intention to reduce nicotine levels – was published in The New England Journal of Medicine in 2015. The authors of the study, led by the Center for the Evaluation of Nicotine in Cigarettes, concluded that 22nd Century’s proprietary Very Low Nicotine SPECTRUM cigarettes were “associated with reductions in smoking, nicotine exposure, and nicotine dependence, with minimal evidence of nicotine withdrawal, compensatory smoking, or serious adverse events.” Links and a brief summary of 17 completed clinical trials using the 22nd Century’s Very Low Nicotine cigarettes are provided at the Company’s website. Today there are at least 25 ongoing clinical trials using 22nd Century’s proprietary Very Low Nicotine cigarettes.
“We are thrilled that FDA is now moving to lower nicotine in combustible cigarettes to non-addictive levels; this is a technically achievable standard whose time has come,” explained Henry Sicignano, III, President and Chief Executive Officer of 22nd Century Group. “With a mountain of science and evidence supporting our Very Low Nicotine products, 22nd Century stands ready to partner with the FDA – and with any Big Tobacco companies that are truly committed to improving the health of American smokers.”
Mr. Sicignano concluded, “Lowering nicotine in cigarettes to non-addictive levels will save millions of lives and billions in healthcare costs; 22nd Century is proud to have such an important role in this public policy imperative.”
Recent XXII News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/10/2024 04:15:19 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/09/2024 08:30:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:30:52 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 09:10:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 01:30:13 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/24/2024 09:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 09:30:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 01:04:11 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 10:02:41 PM
- 22nd Century Secures $3.2 Million to Date in Warrant Exchange Transaction • GlobeNewswire Inc. • 12/04/2023 12:07:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/01/2023 10:18:00 PM
- Pharma Stock Up Big After Second Major Announcement This Week • AllPennyStocks.com • 11/29/2023 03:55:00 PM
- Pharma Stock Up Big After Second Major Announcement This Week • AllPennyStocks.com • 11/29/2023 03:55:00 PM
- 22nd Century Appoints Larry Firestone as Chairman and CEO • GlobeNewswire Inc. • 11/29/2023 12:07:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 09:56:49 PM
- 22nd Century Group Enters into Agreement to Sell Hemp/Cannabis Franchise • GlobeNewswire Inc. • 11/27/2023 09:44:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 11:01:36 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 10:19:32 PM
- 22nd Century Group Continues VLN® Expansion, Now Retailing in More Than 5,100 Stores • GlobeNewswire Inc. • 11/08/2023 06:15:00 PM
- 22nd Century Group (XXII) Expands Reduced Nicotine Content Tobacco IP with Latest Technology License • GlobeNewswire Inc. • 11/07/2023 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 12:30:19 PM
- 22nd Century Group (XXII) Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/06/2023 12:30:00 PM
- 22nd Century Group (XXII) Supports FDA Policy Advancements, Proposed Menthol Ban Now at OMB • GlobeNewswire Inc. • 10/26/2023 12:30:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM